Categories: News

Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit

Motion underscores that Abacus’s claims lack merit as Lapetus, its key life expectancy provider, shut its doors August 31

- Advertisement -

FORT WASHINGTON, Pa., Sept. 3, 2025 /PRNewswire/ — Coventry First LLC (“Coventry”) and its Co-Founder and Executive Chairman, Alan H. Buerger, today announced that they have filed a Motion to Dismiss the complaint brought by Abacus Global Management, Inc. (“Abacus”) (NASDAQ: ABL) in the U.S. District Court for the Middle District of Florida on August 29, 2025. The full Motion to Dismiss can be found here.

- Advertisement -

In the filing, Coventry and Mr. Buerger express their view that Abacus’s lawsuit is an effort to silence constitutionally protected debate. As the Motion states:

- Advertisement -

“The First Amendment expresses ‘a profound national commitment to the principle that debate on public issues should be uninhibited, robust, and wide-open.’ Abacus, however, seeks to flip that principle on its head. Faced with criticism about serious problems of its own making, Abacus brought this meritless lawsuit to muzzle those who have highlighted the truth or expressed their constitutionally protected opinions. That it cannot do.”

- Advertisement -

The Motion also highlights that Abacus invested in and relied heavily upon Lapetus Solutions, Inc. (“Lapetus”) as its primary life expectancy provider — but Lapetus publicly announced that it shut down all operations effective August 31, 2025. This development underscores the concerns raised regarding Abacus’s practices and the importance of open debate about the life settlement industry. 

- Advertisement -

“Abacus’s complaint is an attempt to silence robust debate on important issues affecting the life settlement industry, including the reliability of life expectancy estimates,” said Mr. Buerger. “Transparent disclosures advance the interests of investors, regulators, and the life settlement market as a whole, and the First Amendment protects the right to voice opinions and concerns, particularly on matters of such public interest.”

- Advertisement -

About Coventry

- Advertisement -

Coventry is the leader and creator of the secondary market for life insurance. For more than 20 years, we have been driving the industry forward and expanding opportunities for life insurance policyowners. Coventry’s deep experience combined with a fierce commitment to consumer rights makes Coventry the clear market leader, a position we use to raise industry standards and expand consumer choice. To date, we have delivered more than $6 billion to policyowners who no longer have a need for their policies. To learn more about Coventry, please visit Coventry.com. 

- Advertisement -

Media Contacts:

- Advertisement -

Prosek Partners for Coventry
Andy Merrill / Kiki Tarkhan
Pro-Coventry@prosek.com 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/coventry-and-alan-buerger-move-to-dismiss-abacus-lawsuit-302544516.html

- Advertisement -

Recent Posts

Charles Winslow Completes Annual Internal Strategic Review at Lumena Intelligent Alliance Office

Jersey City, NJ, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Lumena Intelligent Alliance Office confirmed that…

7 hours ago

DebitMyData Human Energy Grid: The Trillion-Dollar Infrastructure Play That Genesis Executive Order Validates

DebitMyData™ Logo FORT LAUDERDALE, Fla., Dec. 25, 2025 (GLOBE NEWSWIRE) -- DebitMyData, Inc., having oversubscribed…

7 hours ago

Yoolax Announces a Milestone 2025 of Growth, Smart Innovation, and Customer Trust

HongKong, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Yoolax, a leading brand in the motorized window…

7 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

10 hours ago

ImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain

December 24, 2025 13:05 ET  | Source: ImmuCell Corporation PORTLAND, Maine, Dec. 24, 2025 (GLOBE…

10 hours ago

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK)…

10 hours ago